Annovis Bio (ANVS) Competitors $2.56 -0.04 (-1.58%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$2.58 +0.02 (+0.82%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, GNFT, CTMX, EPRX, VTYX, TVGN, CRBU, CYBN, OGI, and DMACShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), GENFIT (GNFT), CytomX Therapeutics (CTMX), Eupraxia Pharmaceuticals (EPRX), Ventyx Biosciences (VTYX), Semper Paratus Acquisition (TVGN), Caribou Biosciences (CRBU), Cybin (CYBN), Organigram Global (OGI), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals Ventyx Biosciences Semper Paratus Acquisition Caribou Biosciences Cybin Organigram Global DiaMedica Therapeutics Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Is ANVS or ALXO more profitable? ALX Oncology's return on equity of -104.43% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% ALX Oncology N/A -104.43%-77.74% Does the media refer more to ANVS or ALXO? In the previous week, Annovis Bio and Annovis Bio both had 2 articles in the media. ALX Oncology's average media sentiment score of 0.94 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ANVS or ALXO? Annovis Bio has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Which has stronger valuation and earnings, ANVS or ALXO? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.18ALX OncologyN/AN/A-$134.85M-$2.47-0.27 Do insiders & institutionals have more ownership in ANVS or ALXO? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 21.0% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ANVS or ALXO? Annovis Bio presently has a consensus target price of $18.00, indicating a potential upside of 603.40%. ALX Oncology has a consensus target price of $3.30, indicating a potential upside of 387.59%. Given Annovis Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryALX Oncology beats Annovis Bio on 7 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$50.66M$2.96B$5.45B$20.64BDividend YieldN/A2.46%4.61%3.67%P/E Ratio-1.1817.1129.9028.40Price / SalesN/A312.73449.4255.99Price / CashN/A41.8536.4223.21Price / Book3.827.318.184.33Net Income-$24.59M-$54.43M$3.26B$996.14M7 Day Performance1.95%0.01%6.13%1.97%1 Month Performance-5.57%1.33%0.94%-0.84%1 Year Performance-66.77%8.65%28.86%14.34% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio1.4607 of 5 stars$2.56-1.6%$18.00+603.4%-69.0%$50.66MN/A-1.183News CoverageUpcoming EarningsALXOALX Oncology3.7295 of 5 stars$0.59+13.2%$3.30+462.5%-74.3%$27.66MN/A-0.2440Upcoming EarningsGNFTGENFIT1.6065 of 5 stars$3.79-0.3%$13.00+243.0%-8.8%$190.01M$76.77M0.00120Gap UpCTMXCytomX Therapeutics3.9984 of 5 stars$2.39+1.7%$5.75+140.6%+99.2%$189.46M$138.10M4.98170News CoverageGap DownEPRXEupraxia Pharmaceuticals2.7529 of 5 stars$5.37+2.0%$11.00+105.0%+108.7%$189.15MN/A-7.0629VTYXVentyx Biosciences2.7938 of 5 stars$2.72+3.4%$10.00+267.6%+41.9%$187.15MN/A-1.5530News CoverageEarnings ReportUpcoming EarningsAnalyst UpgradeGap UpTVGNSemper Paratus Acquisition3.6611 of 5 stars$0.99-0.7%$10.00+907.5%+46.7%$183.88MN/A0.003CRBUCaribou Biosciences2.4494 of 5 stars$2.10+7.7%$8.50+304.8%-14.4%$181.36M$9.99M-1.30100Gap UpCYBNCybin2.8549 of 5 stars$7.68+1.6%$85.00+1,006.8%N/A$181.17MN/A-1.7550OGIOrganigram Global1.2058 of 5 stars$1.38+3.8%N/A-6.2%$178.26M$117.47M13.80860Upcoming EarningsDMACDiaMedica Therapeutics1.7522 of 5 stars$4.36+5.8%$10.75+146.6%+39.4%$176.68MN/A-6.8120 Related Companies and Tools Related Companies ALX Oncology Competitors GENFIT Competitors CytomX Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Ventyx Biosciences Competitors Semper Paratus Acquisition Competitors Caribou Biosciences Competitors Cybin Competitors Organigram Global Competitors DiaMedica Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANVS Stock Alerts